A growing legal and political dispute is unfolding in the United States over the federal government’s decision to grant temporary exemptions from air-pollution rules to dozens of medical device sterilization facilities that use ethylene oxide, a gas widely recognized as a potent carcinogen.

The controversy centers on exemptions issued under the Clean Air Act that allow certain facilities to delay or avoid compliance with strict emission limits finalized in 2024. Those limits, introduced as part of a broader effort to reduce hazardous air pollutants, require commercial sterilizers to cut ethylene oxide emissions by roughly 90 percent. Ethylene oxide is commonly used to sterilize medical equipment that cannot withstand high heat, but long-term exposure has been linked in scientific studies to elevated risks of several cancers, including breast and lymphatic cancers.

Under the 2024 rule, companies were given two years to install new pollution-control systems, upgrade monitoring, and, in some cases, construct specialized enclosures designed to capture and destroy the gas before it escapes into surrounding communities. Federal regulators estimated that compliance across the industry would cost more than $300 million. While the price tag was significant, the rule was justified as a necessary public-health measure, particularly for neighborhoods located near sterilization plants.

Many of these facilities operate in or near residential areas, sometimes close to schools and child-care centers. Public-health advocates have long argued that people living near sterilizers face disproportionate exposure risks, especially where facilities have historically emitted ethylene oxide without advanced controls.

Despite the compliance timeline, a change in federal leadership opened the door for companies to seek presidential exemptions. The Environmental Protection Agency created a special process allowing facilities to submit email requests for relief, arguing why they could not meet the standards on time. Hundreds of industrial operators across multiple sectors applied for similar exemptions from various Clean Air Act rules, but medical sterilizers emerged as one of the most active groups.

Roughly 40 of the nation’s approximately 90 commercial sterilization plants ultimately received exemptions through presidential proclamations. Industry representatives argued that supply-chain constraints, limited availability of specialized equipment, and workforce shortages made it difficult to meet the regulatory deadlines. They also contended that sterilization services are critical to the medical supply chain and that disruptions could affect the availability of sterile equipment used in hospitals and clinics.

The Clean Air Act allows the president to grant limited exemptions if two conditions are met: the required technology must be unavailable, and the exemption must be in the national interest. Facilities seeking relief maintained that both criteria applied, citing delays in manufacturing and installing control technologies.

However, environmental organizations and community groups have challenged that interpretation in court. A coalition of nonprofits recently filed a lawsuit in federal court seeking to overturn the exemptions, arguing that the legal threshold for granting them was not met. The plaintiffs contend that many facilities were already on track to comply, and some had even completed major upgrades before the exemptions were issued.

According to regulatory records, only a small fraction of sterilizers already met the full 2024 standards at the time the rule was finalized, but several met portions of the requirements. Others were in the process of installing permanent total enclosures, one of the most effective — and costly — pollution-control options. Critics say the existence of functioning technology and ongoing compliance efforts undermines claims that the standards were unattainable.

Data from state agencies also reveal uneven patterns in how exemptions were distributed. Some states with large numbers of sterilizers saw relatively few exemptions, partly because facilities there had already complied with most requirements. Other states, despite having fewer facilities overall, received exemptions for all or most of their plants. In at least one case, a facility that had reportedly met standards years earlier still received an exemption, raising questions among advocates about how determinations were made.

Environmental groups argue that the exemptions reduce incentives for companies to operate and maintain expensive control equipment. Even facilities that already installed pollution controls may save money by scaling back monitoring or maintenance if enforcement is relaxed. Advocates say this creates a financial motive to delay full compliance, potentially prolonging emissions in nearby communities.

State-level regulators in some regions had been working with companies to update permits and install controls before the exemptions were announced. In certain cases, those efforts have slowed or been postponed as a result of the federal relief.

The legal battle now underway could clarify how far presidential authority extends under the Clean Air Act. Courts will likely examine whether the statutory criteria for exemptions were satisfied and whether the decisions were supported by evidence about technology availability and national interest.

Meanwhile, communities living near sterilization plants remain at the center of the debate. For residents, the issue is not only regulatory but deeply personal, tied to concerns about long-term health, environmental justice, and trust in environmental oversight.

As lawsuits proceed and more cases move through the judicial system, the outcome may shape how future administrations balance industrial needs, public health protections, and the limits of executive power under environmental law.